Comparison of Clinical, Pathological, and Prognostic Features in Mutant and Wild-Type Male Breast Cancer Patients.

Objective: Published studies on male breast cancer (MBC) and mutations are scarce and usually include, a small number of patients. The clinicopathological characteristics of mutant and wild-type MBC patients were compared in more than forty patients in this study.

Materials And Methods: A retrospective review of MBC patients' clinical and histopathological data was conducted. To compare the patients' characteristics, chi-square test and Fisher's Exact test were utilized. Kaplan-Meier analysis was used to examine the survival analysis.

Results: In total 43 cases were reviewed. The average duration of follow-up was 35.8 months. mutations were found in 11 (25.6%) of the patients. mutations were found in four patients (9.3%), mutations in six patients (14%), and and mutations in one patient (2.3%). The median age at diagnosis was 58 years old, and there was no statistically significant difference between groups ( = 0.7). Tumor location ( = 0.3), human epidermal growth factor receptor 2 overexpression ( = 0.5), estrogen receptor status ( = 0.05), progesterone receptor status ( = 0.6), tumor stage ( = 0.9), lymph node positivity ( = 0.5), tumor histology ( = 0.06), and recurrence status ( = 0.6) were similar between -wild type and -mutated patients. Overall survival averaged 115.6 months (range: 76.0-155.3), with no statistically significant differences between groups ( = 0.6).

Conclusion: This study investigated clinical and pathological characteristics and prognoses of wild and mutant-type MBC and these were similar in all groups studied.